BRAVENKnow what's real. Now.
Tuesday, July 28, 2026
world1 outlet covering thisCalibrating

CG Oncology bladder cancer trial results published in Lancet

First publishedJul 27, 22:52 UTC
Last updatedJul 28, 03:24 UTC · 5m ago
11 outletInvesting.com · Company News
Investing.com · Company News5CG Oncology bladder cancer trial results published in LancetOpen ↗
1 outlets over time — hover a bar for its window & outletslast updated
CG Oncology bladder cancer trial results published in Lancet
● Story signals

How strong is this topic?

5.5/10Significanceimpact & urgency
5.0/10Source trustoutlet authority
1Outletsindependent sources

Significance weighs impact, urgency & coverage breadth · Source trust is the outlets' average authority · more outlets means a more confirmed story.

Answer

(NASDAQ:CGON) announced today that results from its Phase 3 BOND-003 Cohort C trial have been published in The Lancet Oncology, according to a press release statement. The trial evaluated cretostimogene grenadenorepvec monotherapy in patients with high-risk, Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without Ta/T1 disease.

Reported by 1 outlet — Investing.com · Company News. See all sources ↓

(NASDAQ:CGON) announced today that results from its Phase 3 BOND-003 Cohort C trial have been published in The Lancet Oncology, according to a press release statement. The trial evaluated cretostimogene grenadenorepvec monotherapy in patients with high-risk, Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without Ta/T1 disease. The trial met its primary endpoint with 75.5% of patients achieving a complete response at any time after receiving treatment. The median duration of response reached at least 27.9 months and is ongoing.

Read the full report at Investing.com · Company News ↗

Why it matters

A world story we're tracking; its significance and source trust firm up as more outlets confirm it.

In brief
What's the story?
(NASDAQ:CGON) announced today that results from its Phase 3 BOND-003 Cohort C trial have been published in The Lancet Oncology, according to a press release statement. The trial evaluated cretostimogene grenadenorepvec monotherapy in patients with high-risk, Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without Ta/T1 disease.
How widely is it covered?
1 outlet, average source rating 5.0/10.
When was it last updated?
5m ago.
Different angles across outlets
Coverage map

How outlets are framing the same story

Here's how each outlet is covering the story — compare their headlines and timing at a glance.

  • Coverage card1 outlet
    1Coverage
    Scouting report

    CG Oncology bladder cancer trial results published in Lancet

    Sources1
    TypeCoverage
    Investing.com · Company News
Related in the knowledge graph
organizationBondorganizationCG OncologyorganizationCG Oncology IncorganizationCGONorganizationCohortorganizationLancet. DALLASorganizationNasdaqorganizationPhase
Sources (1)
Avg source rating 5.0/10
Processing cluster
A1A2A3B1B2B3
Share this article
X / TwitterLinkedInWhatsApp
Summarize with AI (opens AI chat with article URL · Gemini: prompt copied to clipboard)
GPTPerplexityGeminiClaude